Aims Statin intolerance (SI) represents a significant public health problem for which precise
estimates of prevalence are needed. Statin intolerance remains an important clinical …

Recent years have brought a significant amount of new results in the field of atherosclerosis.
A better understanding of the role of different lipoprotein particles in the formation of …

Background Lowering the blood cholesterol level may reduce the risk of coronary heart
disease. This double-blind study was designed to determine whether the administration of …

Context.—The Lifestyle Heart Trial demonstrated that intensive lifestyle changes may lead to
regression of coronary atherosclerosis after 1 year. Objectives.—To determine the feasibility …

ContextPrior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of
atherosclerosis progression with statin therapy but have not shown convincing evidence of …

ContextStatin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and
mortality. However, the optimal strategy and target level for lipid reduction remain uncertain …

Lipid lowering therapy has been the mainstay of cardiovascular risk reduction and
prevention. Statin drugs have been shown to reduce serum cholesterol along with significant …

Context Theory and simulation suggest that randomized controlled trials (RCTs) stopped
early for benefit (truncated RCTs) systematically overestimate treatment effects for the …

Context Although low levels of high-density lipoprotein cholesterol (HDL-C) increase risk for
coronary disease, no data exist regarding potential benefits of administration of HDL-C or an …

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with
skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild …